Brodalumab in the treatment of moderate-to-severe psoriasis in patients refractory to anti-interleukin-17A therapies: Evaluation of secondary endpoints. (2021). SKIN The Journal of Cutaneous Medicine, 5(5), 524-529. https://doi.org/10.25251/skin.5.5.10